Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
ASMI technische analyse
Volgen
en het bericht klopt inhoudelijk ook niet want de wpa was in 2016 veel hoger dan het bedrag in het bericht waarnaar verwezen wordt.
Jatoch! schreef op 28 februari 2018 09:40 :
volgens mij is dit nepnieuws want de Q4 cijfers komen pas vanmiddag na beurs....
het is een beursblik. Automatisch gegenereerd volgens mij.
Jatoch! schreef op 28 februari 2018 09:43 :
en het bericht klopt inhoudelijk ook niet want de wpa was in 2016 veel hoger dan het bedrag in het bericht waarnaar verwezen wordt.
Dat dacht ik ook.. mocht het waar zijn dan donderd de boel ook met 10% in
2016 , was de nettowinst 135,6 mil. op 60,6 mil aandelen = 2,23 wpa 2017 , is 210 mil. verdient t/m derde kwartaal. Tel daar gemiddeld 40 mil voor het vierde kwartaal bij op =250 mil op 55 mil aandelen = 4,54 wpa. Zo staat althans in de cijferberichten vermeldt wat overeenkomt met de gegevens in de fundamentele analyse (op IEX). Graag correctie als dat niet klopt .
Dezelfde cijfers vermeldt in het jaarverslag 2016 op mcenv.blogspot.nl/2017/04/jaarverslag...
In 2017 heeft ASMI voor 350 mil.eigen aandelen gekocht . In nov. 2017 belooft onderneming 475 mil. aan aandelhouders uit te keren.
Beetje triest eigenlijk hoe ASMI is achtergebleven bij een Besi en een ASML. Besi dit jaar 16,4% up ASML dit jaar 12% up ASMI dit jaar slechts 4,7% En dat in een booming business. En vandaag vallen ze ook niet over elkaar heen om het te kopen voor de cijfers. Maar er wordt flink minder winst verw8 heb ik gelezen. dus valt het nu mss mee
Bericht van Thomson Reuters gaat enkel over het vierde kwartaal.
Nou, ben lang niet zo benieuwd geweest naar de cijfers! Analysten consensus: Q4 winst = 0.73 WPA Q1 rev = ongeveer 190m
MJansen schreef op 28 februari 2018 17:52 :
Nou, ben lang niet zo benieuwd geweest naar de cijfers!
Je bent zo ongeveer de enige nog.
Vorig jaar juli zat de halve goegemeenschap te w88. toen werd het 1 groot fiasco
volgens mij was de fiasco niet ASMI, maar ASM PT, zoals altijd het geval is met die prutsers in HK... Maar eens zien wat ze er nu van gebakken hebben daar. Ik ben iig wel voorzichtig optimistisch gezien de tempo van de aandelenterugkoop afgelopen tijd.
MJansen schreef op 28 februari 2018 17:59 :
volgens mij was de fiasco niet ASMI,
Niet de cijfers, maar de koers de andere dag
Wat is de reden om na beurs de cijfers bekend te maken? Ik had er meer van verwacht vandaag. Hopelijk worden de cijfers goed ontvangen morgen
Mathias kemena schreef op 28 februari 2018 18:05 :
Wat is de reden om na beurs de cijfers bekend te maken?
Ik had er meer van verwacht vandaag. Hopelijk worden de cijfers goed ontvangen morgen
ASMPT is voorbeurs nog aan het traden. ASMPT cijfers zijn deels ook af te leiden uit ASMI cijfers natuurlijk. Cijfers ASMI zijn goed. 0.79 EPS, dus dat is een beat op de 0.73 consensus. Outlook weet ik zo niet. Wel ander goed nieuws: er komt een dividend van 4 euro aan, plus een nieuw inkoopprogramma van €250m.
Almere, The Netherlands February 28, 2018 ASM International N.V. (Euronext Amsterdam: ASM) today reports its fourth quarter 2017 operating results (unaudited) in accordance with IFRS. FINANCIAL HIGHLIGHTS Quarter EUR million Q4 2016 Q3 2017 Q4 2017 New orders 176.9 160.4 203.2 Net sales 172.6 185.3 205.6 Gross profit margin % 44.9 % 40.0 % 39.3 % Operating result 29.9 25.7 34.9 Result from investments (excluding amortization intangible assets resulting from the sale of the 12% stake of ASMPT) 18.4 32.1 14.0 Amortization intangible assets resulting from the sale of the 12% stake of ASMPT (7.0 ) (5.4 ) (4.6 ) Result from sale of ASMPT stake - - 183.9 Net earnings 61.5 42.2 224.8 Normalized net earnings (excluding amortization intangible assets resulting from the sale of the 12% stake of ASMPT and result from sale and dilution of ASMPT stake) 68.5 47.6 45.5 · New orders at €203 million were 27% above the Q3 2017 level and 15% above the level of Q4 2016. · Net sales for the fourth quarter 2017 were €206 million, an increase of 11% compared to the previous quarter. Year-on-year net sales increased with 19%. · Operating result increased to €35 million. This increase is mainly the result of higher sales. · Normalized net earnings for the fourth quarter 2017 decreased by €2 million compared to the third quarter 2017. The €18 million decrease of the result of investment is partly offset by the better operating result of ASMI (+€9 million), lower negative effects of currencies (+€3 million), and the recognition of net losses, mainly in the USA (+€4 million). COMMENT Commenting on the results Chuck del Prado said: "In Q4 we realized sales of €206 million and an order intake of €203 million. Our sales were well in line with our guidance while order intake was substantially higher. Our sales included again several deliveries of Intrepid Epitaxy and PECVD systems. As earlier mentioned these products show initially lower margins. The margin on those products showed a clear improvement within the quarter, however this improvement was offset by some incidental results. We expect our gross margin to normalize again in the course of 2018." OUTLOOK For Q1 and Q2, on a currency comparable level, we expect sales respectively of €155-175 million and €200-230 million. The broader range for Q2 reflects some uncertainty around the exact timing of individual tool shipments. For Q1, on a currency comparable level, we expect an order intake of €190-210 million. For 2018, market watchers currently expect the wafer fab equipment market to increase with, on average, a high single digit percentage. We aim to outgrow the wafer fab equipment market in 2018. SHARE BUYBACK PROGRAM AND CAPITAL REPAYMENT During the Annual General Meeting of Shareholders of May 22, 2017, the Board was authorized to acquire up to 10% of ASMI shares for a period of 18 months. On April 24, 2017, ASMI announced a partial sale of a stake of approximately 5% of in ASMPT, whereby ASMI indicated to use the proceeds of approximately €245 million for a new share buyback program. The start of this new program for a total amount of €250 million was announced on September 22, 2017. At that time, ASMI also announced that it had the intention to reduce its capital by withdrawing the repurchased shares after having received the approval from its shareholders. The repurchase program is part of ASMI's commitment to use excess cash for the benefit of its shareholders. On December 31, 2017, 60.0% of the program was completed at an average share price of €56.77, while as per February 23, 2018, 96% of the program was completed. On November 2, 2017, ASMI announced a partial sale of a stake of approximately 9% in ASMPT, whereby ASMI received proceeds of approximately €445 million. ASMI intends to propose to the 2018 Annual General Meeting to distribute €4.00 per common share free of any withholding tax. To this end it is proposed that the distribution is effected as a repayment of capital to the shareholders by way of a reduction of the par value of the common shares. Moreover ASMI plans to use €250 million for a new share buyback program. As of February 23, 2018, ASMI held 7.8 million treasury shares (at the end of 2017: 6.16 million), which is more than sufficient to cover our outstanding options and restricted/performance shares. Hence ASMI will propose to the Annual General Meeting, to be held on May 28, 2018, the cancellation of 6 million treasury shares. ASMI will propose to the forthcoming 2018 Annual General Meeting Shareholders, to declare a dividend of €0.80 per common share. About ASM International ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly & packaging and surface mount technology (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI's website at www.asm.com. Cautionary Note Regarding Forward-Looking Statements: All matters discussed in this press release, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the success of restructurings, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholders or other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability, epidemics and other risks indicated in the Company's reports and financial statements. The Company assumes no obligation nor intends to update or revise any forward-looking statements to reflect future developments or circumstances. ASM International will host an investor conference call and web cast on Thursday, March 1, 2018 at 15:00 Continental European Time (10:00 a.m. - US Eastern Time). The teleconference dial-in numbers are as follows: · United States: +1 646 828 8193 · International: +44 (0)330 336 9411 · The Netherlands: +31 (0)20 703 8261 · Access Code: 6043871 A simultaneous audio webcast and replay will be accessible at www.asm.com. CONTACT Investor contact: Victor Bareño T: +31 88 100 8500 E: victor.bareno@asm.com Media contact: Ian Bickerton T: +31 625 018 512 Press Release Fourth Quarter Results
Zie ik het verkeerd of zijn de verwachtingen voor Q1 aan de magere kant?
Q4 cijfers zien er geweldig uit. Ook nog 4 euro extra uitkering ivm gedeeltelijke verkoop aandelen ASMPT.
Q1 is volgens mij altijd wat minder bij ASMI. Seasonal iets volgens mij. Er zijn 2 dingen die ik meeneem: 1) Marges van de nieuwe producten zijn stuk verbeterd (enkel nu offset door one off lasten). Dus we kunnen weer terug richting de 44% bruto marges denk ik. 2) ASMI verwacht dus minimaal 10% groei in de omzet te gaan realiseren over 2018. Dat is een omzet van grofweg 800m. De markt gaat uit van 785, dus dat lijkt gewoon cf de verwachtingen Dan blijft er nog over 10% hogere EPS dan verwacht. PT kan ik zo niet beoordelen, maar die lijkt ook meer winst te hebben gemaakt (gecorrigeerd voor kleinere stake miv dit kwartaal).
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)